Paragon 28 Inc (FNA)
9.93
+0.23
(+2.37%)
USD |
NYSE |
Nov 15, 11:53
Paragon 28 Research and Development Expense (Quarterly): 7.083M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 7.083M |
| March 31, 2024 | 7.584M |
| December 31, 2023 | 8.102M |
| September 30, 2023 | 7.244M |
| June 30, 2023 | 7.683M |
| March 31, 2023 | 7.049M |
| December 31, 2022 | 6.55M |
| September 30, 2022 | 6.337M |
| Date | Value |
|---|---|
| June 30, 2022 | 5.99M |
| March 31, 2022 | 5.773M |
| December 31, 2021 | 4.874M |
| September 30, 2021 | 4.118M |
| June 30, 2021 | 3.587M |
| March 31, 2021 | 3.549M |
| December 31, 2020 | 2.997M |
| September 30, 2020 | 2.346M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.346M
Minimum
Sep 2020
8.102M
Maximum
Dec 2023
5.679M
Average
6.164M
Median
Research and Development Expense (Quarterly) Benchmarks
| Outset Medical Inc | 8.139M |
| Perspective Therapeutics Inc | 9.275M |
| Retractable Technologies Inc | 0.1991M |
| Xtant Medical Holdings Inc | 0.636M |
| Catheter Precision Inc | 0.081M |